Liquidia (LQDA) Net Cash Flow Growth (1y) (2021 - 2026)
Powered by 
Analysis
Liquidia (LQDA) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.43 Bn | 625.67 Bn | 17.26 Bn | 93.66% |
| 2 | AbbVie | 442.46 Bn | 435.89 Bn | 12.70 Bn | -323.06% |
| 3 | Merck | 366.77 Bn | 359.63 Bn | 12.21 Bn | 248.11% |
| 4 | Novartis Ag | 266.59 Bn | 258.90 Bn | 11.24 Bn | 195.58% |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | -517.34% |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | -88.52% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 3,465.10% |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 270.63% |
| 10 | Liquidia | 6.11 Bn | 5.82 Bn | 160.92 Mn | 756.52% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 756.52% |
| Mar 31, 2026 | 577.70% |
| Dec 31, 2025 | 218.99% |
| Sep 30, 2025 | -122.34% |
| Jun 30, 2025 | 128.94% |
| Mar 31, 2025 | -109.06% |
| Dec 31, 2024 | -474.15% |
| Sep 30, 2024 | 695.40% |
| Jun 30, 2024 | -298.41% |
| Mar 31, 2024 | 6,470.33% |
| Dec 31, 2023 | 247.98% |
| Sep 30, 2023 | -116.87% |
| Jun 30, 2023 | -113.50% |
| Mar 31, 2023 | 276.33% |
| Dec 31, 2022 | 23.22% |
| Sep 30, 2022 | -43.90% |
| Jun 30, 2022 | 223.06% |
| Mar 31, 2022 | 102.57% |
| Dec 31, 2021 | 53.91% |
| Sep 30, 2021 | -106.85% |